Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TrivarX Limited ( (AU:TRI) ) has provided an announcement.
TrivarX Limited has successfully enrolled 30 patients in a clinical trial at the West Los Angeles VA Medical Center, aimed at evaluating its novel single-lead ECG algorithm for screening major depressive episodes in veterans with suspected sleep apnea. The trial, conducted in collaboration with the Greater Los Angeles Research and Education Foundation and Veterans Affairs Greater Los Angeles Healthcare System, utilizes heart rate and heart rate variability metrics for sleep staging and depression detection. The company anticipates that the forthcoming interim results will provide insights into the algorithm’s effectiveness and its potential for commercialization.
More about TrivarX Limited
TrivarX Limited is a mental health technology company that focuses on pioneering the use of objective measures for early detection and screening of mental health conditions. Founded in Australia, it operates with offices in Perth and Minneapolis and is listed on the Australian Securities Exchange and OTCQB Venture Market.
YTD Price Performance: -37.50%
Average Trading Volume: 1,453,458
Technical Sentiment Signal: Sell
Current Market Cap: A$6.2M
For a thorough assessment of TRI stock, go to TipRanks’ Stock Analysis page.